CABA · Cabaletta Bio, Inc.
$2.75
-0.08 (-2.83%)
At close · Jul 20
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions that raise substantial doubt about our ability to continue as a going concern. If we are unable to secure additional funding beyond our current cash position that enables our operations into mid-2027, we may be forced to delay, reduce or discontinue our product development programs efforts or other operations.”View the 10-Q filed May 14, 2026
Market Cap
$448.40M
Shares
163.05M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$167.86M
-44.9%
FY2025
Diluted EPS
-$2.10
+10.3%
FY2025
Operating Cash Flow
-$131.08M
-48.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $151.01M | $142.67M | $97.2M | $55.42M | $39.3M | $32.49M | $21.38M | $11.67M | |
| $28.39M | $29.57M | $27.94M | $19.24M | $14.84M | $13.82M | $12.46M | $7.01M | |
| $179.4M | $172.24M | $125.14M | $74.66M | $54.14M | $46.31M | $33.83M | $18.68M | |
| -$179.4M | -$172.24M | -$125.14M | -$74.66M | -$54.14M | -$46.31M | -$33.83M | -$18.68M | |
| $2.35M | $2M | $748K | — | — | — | — | — | |
| $5.62M | $6.03M | $10.03M | $6.99M | $1.16M | $24K | $494K | $1.74M | |
| $0 | $0 | — | — | — | — | — | — | |
| -$175.43M | -$167.86M | -$115.86M | -$67.68M | -$52.98M | -$46.29M | -$33.34M | -$16.94M | |
| — | — | — | — | — | — | -$33.34M | -$22.27M | |
| -$175.43M | -$167.83M | -$115.9M | -$67.59M | -$53.02M | -$46.29M | -$33.33M | — | |
| USD/shares | — | -$2.10 | -$2.34 | -$1.65 | -$1.81 | — | — | — |
| USD/shares | — | -$2.10 | -$2.34 | -$1.65 | -$1.81 | — | — | — |
| shares | — | — | 1.17M | 1.17M | 5.94M | — | — | — |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.46×
EV/EBIT
—
Biotechnology median 26.20×
P/E (TTM)
—
Biotechnology median 7.03×